APO Research
Talk to an analyst

APO RESEARCH · REPORT

High Affinity Nerve Growth Factor Receptor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global High Affinity Nerve Growth Factor Receptor Market Outlook and Growth Opportunities 2026

19 December 2025205 pages

Choose your research edition.

Industry ResearchHigh Affinity Nerve Growth Factor Receptor Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal High Affinity Nerve Growth Factor Receptor Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal High Affinity Nerve Growth Factor Receptor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal High Affinity Nerve Growth Factor Receptor Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal High Affinity Nerve Growth Factor Receptor Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global High Affinity Nerve Growth Factor Receptor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for High Affinity Nerve Growth Factor Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for High Affinity Nerve Growth Factor Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for High Affinity Nerve Growth Factor Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the High Affinity Nerve Growth Factor Receptor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the High Affinity Nerve Growth Factor Receptor market include Merck & Co Inc, AstraZeneca Plc, Tiziana Life Sciences Plc, Sienna Biopharmaceuticals Inc, Rottapharm Biotech Srl, Proximagen Ltd, Plexxikon Inc, Nerviano Medical Sciences Srl and Loxo Oncology Inc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global High Affinity Nerve Growth Factor Receptor market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of High Affinity Nerve Growth Factor Receptor and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents High Affinity Nerve Growth Factor Receptor revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global High Affinity Nerve Growth Factor Receptor market.

High Affinity Nerve Growth Factor Receptor Segment by Company

Merck & Co Inc

AstraZeneca Plc

Tiziana Life Sciences Plc

Sienna Biopharmaceuticals Inc

Rottapharm Biotech Srl

Proximagen Ltd

Plexxikon Inc

Nerviano Medical Sciences Srl

Loxo Oncology Inc

Ignyta Inc

Handok Inc

Genzyme Corp

Dompe Farmaceutici SpA

Daiichi Sankyo Co Ltd

Astellas Pharma Inc

Array BioPharma Inc

High Affinity Nerve Growth Factor Receptor Segment by Type

Cenegermin

CRB-0089

BNN-27

AZD-7451

ASP-7962

Others

High Affinity Nerve Growth Factor Receptor Segment by Application

Low Back Pain

Papillary Thyroid Cancer

Lung Cancer

Bile Duct Cancer

Others

High Affinity Nerve Growth Factor Receptor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global High Affinity Nerve Growth Factor Receptor status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the High Affinity Nerve Growth Factor Receptor key companies, revenue, market share, and recent developments.

3. To split the High Affinity Nerve Growth Factor Receptor breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions High Affinity Nerve Growth Factor Receptor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify High Affinity Nerve Growth Factor Receptor significant trends, drivers, influence factors in global and regions.

6. To analyze High Affinity Nerve Growth Factor Receptor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global High Affinity Nerve Growth Factor Receptor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of High Affinity Nerve Growth Factor Receptor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of High Affinity Nerve Growth Factor Receptor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global High Affinity Nerve Growth Factor Receptor industry.

Chapter 3: Detailed analysis of High Affinity Nerve Growth Factor Receptor company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of High Affinity Nerve Growth Factor Receptor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of High Affinity Nerve Growth Factor Receptor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. High Affinity Nerve Growth Factor Receptor Industry Trends Table 2. High Affinity Nerve Growth Factor Receptor Industry Drivers Table 3. High Affinity Nerve Growth Factor Receptor Industry Opportunities and Challenges Table 4. High Affinity Nerve Growth Factor Receptor Industry Restraints Table 5. Global High Affinity Nerve Growth Factor Receptor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global High Affinity Nerve Growth Factor Receptor Revenue Share by Company (2021-2026) Table 7. Global High Affinity Nerve Growth Factor Receptor Company Ranking, (2024-2026) & (US$ Million) Table 8. Global High Affinity Nerve Growth Factor Receptor Key Company Manufacturing Base & Headquarters Table 9. Global High Affinity Nerve Growth Factor Receptor Company, Product Type & Application Table 10. Global High Affinity Nerve Growth Factor Receptor Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global High Affinity Nerve Growth Factor Receptor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cenegermin Table 15. Significant Companies of CRB-0089 Table 16. Significant Companies of BNN-27 Table 17. Significant Companies of AZD-7451 Table 18. Significant Companies of ASP-7962 Table 19. Significant Companies of Others Table 20. Global High Affinity Nerve Growth Factor Receptor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global High Affinity Nerve Growth Factor Receptor Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global High Affinity Nerve Growth Factor Receptor Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global High Affinity Nerve Growth Factor Receptor Sales Value Share by Type (2021-2026) Table 24. Global High Affinity Nerve Growth Factor Receptor Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Low Back Pain Table 26. Significant Companies of Papillary Thyroid Cancer Table 27. Significant Companies of Lung Cancer Table 28. Significant Companies of Bile Duct Cancer Table 29. Significant Companies of Others Table 30. Global High Affinity Nerve Growth Factor Receptor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global High Affinity Nerve Growth Factor Receptor Sales Value by Application (2021-2026) & (US$ Million) Table 32. Global High Affinity Nerve Growth Factor Receptor Sales Value by Application (2027-2032) & (US$ Million) Table 33. Global High Affinity Nerve Growth Factor Receptor Sales Value Share by Application (2021-2026) Table 34. Global High Affinity Nerve Growth Factor Receptor Sales Value Share by Application (2027-2032) Table 35. Global High Affinity Nerve Growth Factor Receptor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global High Affinity Nerve Growth Factor Receptor Sales Value by Region (2021-2026) & (US$ Million) Table 37. Global High Affinity Nerve Growth Factor Receptor Sales Value Share by Region (2021-2026) Table 38. Global High Affinity Nerve Growth Factor Receptor Sales Value by Region (2027-2032) & (US$ Million) Table 39. Global High Affinity Nerve Growth Factor Receptor Sales Value Share by Region (2027-2032) Table 40. Global High Affinity Nerve Growth Factor Receptor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global High Affinity Nerve Growth Factor Receptor Sales Value by Country (2021-2026) & (US$ Million) Table 42. Global High Affinity Nerve Growth Factor Receptor Sales Value Market Share by Country (2021-2026) Table 43. Global High Affinity Nerve Growth Factor Receptor Sales Value by Country (2027-2032) & (US$ Million) Table 44. Global High Affinity Nerve Growth Factor Receptor Sales Value Market Share by Country (2027-2032) Table 45. Merck & Co Inc Company Information Table 46. Merck & Co Inc Business Overview Table 47. Merck & Co Inc High Affinity Nerve Growth Factor Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Merck & Co Inc High Affinity Nerve Growth Factor Receptor Product Portfolio Table 49. Merck & Co Inc Recent Development Table 50. AstraZeneca Plc Company Information Table 51. AstraZeneca Plc Business Overview Table 52. AstraZeneca Plc High Affinity Nerve Growth Factor Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. AstraZeneca Plc High Affinity Nerve Growth Factor Receptor Product Portfolio Table 54. AstraZeneca Plc Recent Development Table 55. Tiziana Life Sciences Plc Company Information Table 56. Tiziana Life Sciences Plc Business Overview Table 57. Tiziana Life Sciences Plc High Affinity Nerve Growth Factor Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Tiziana Life Sciences Plc High Affinity Nerve Growth Factor Receptor Product Portfolio Table 59. Tiziana Life Sciences Plc Recent Development Table 60. Sienna Biopharmaceuticals Inc Company Information Table 61. Sienna Biopharmaceuticals Inc Business Overview Table 62. Sienna Biopharmaceuticals Inc High Affinity Nerve Growth Factor Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Sienna Biopharmaceuticals Inc High Affinity Nerve Growth Factor Receptor Product Portfolio Table 64. Sienna Biopharmaceuticals Inc Recent Development Table 65. Rottapharm Biotech Srl Company Information Table 66. Rottapharm Biotech Srl Business Overview Table 67. Rottapharm Biotech Srl High Affinity Nerve Growth Factor Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Rottapharm Biotech Srl High Affinity Nerve Growth Factor Receptor Product Portfolio Table 69. Rottapharm Biotech Srl Recent Development Table 70. Proximagen Ltd Company Information Table 71. Proximagen Ltd Business Overview Table 72. Proximagen Ltd High Affinity Nerve Growth Factor Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Proximagen Ltd High Affinity Nerve Growth Factor Receptor Product Portfolio Table 74. Proximagen Ltd Recent Development Table 75. Plexxikon Inc Company Information Table 76. Plexxikon Inc Business Overview Table 77. Plexxikon Inc High Affinity Nerve Growth Factor Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Plexxikon Inc High Affinity Nerve Growth Factor Receptor Product Portfolio Table 79. Plexxikon Inc Recent Development Table 80. Nerviano Medical Sciences Srl Company Information Table 81. Nerviano Medical Sciences Srl Business Overview Table 82. Nerviano Medical Sciences Srl High Affinity Nerve Growth Factor Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Nerviano Medical Sciences Srl High Affinity Nerve Growth Factor Receptor Product Portfolio Table 84. Nerviano Medical Sciences Srl Recent Development Table 85. Loxo Oncology Inc Company Information Table 86. Loxo Oncology Inc Business Overview Table 87. Loxo Oncology Inc High Affinity Nerve Growth Factor Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Loxo Oncology Inc High Affinity Nerve Growth Factor Receptor Product Portfolio Table 89. Loxo Oncology Inc Recent Development Table 90. Ignyta Inc Company Information Table 91. Ignyta Inc Business Overview Table 92. Ignyta Inc High Affinity Nerve Growth Factor Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Ignyta Inc High Affinity Nerve Growth Factor Receptor Product Portfolio Table 94. Ignyta Inc Recent Development Table 95. Handok Inc Company Information Table 96. Handok Inc Business Overview Table 97. Handok Inc High Affinity Nerve Growth Factor Receptor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Handok Inc High Affinity Nerve Growth Factor Receptor Product Portfolio Table 99. Handok Inc Recent Development Table 100. Genzyme Corp Company Information Table 101. Genzyme Corp Business Overview Table 102. Genzyme Corp High Affinity Nerve Growth Factor Receptor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Genzyme Corp High Affinity Nerve Growth Factor Receptor Product Portfolio Table 104. Genzyme Corp Recent Development Table 105. Dompe Farmaceutici SpA Company Information Table 106. Dompe Farmaceutici SpA Business Overview Table 107. Dompe Farmaceutici SpA High Affinity Nerve Growth Factor Receptor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Dompe Farmaceutici SpA High Affinity Nerve Growth Factor Receptor Product Portfolio Table 109. Dompe Farmaceutici SpA Recent Development Table 110. Daiichi Sankyo Co Ltd Company Information Table 111. Daiichi Sankyo Co Ltd Business Overview Table 112. Daiichi Sankyo Co Ltd High Affinity Nerve Growth Factor Receptor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Daiichi Sankyo Co Ltd High Affinity Nerve Growth Factor Receptor Product Portfolio Table 114. Daiichi Sankyo Co Ltd Recent Development Table 115. Astellas Pharma Inc Company Information Table 116. Astellas Pharma Inc Business Overview Table 117. Astellas Pharma Inc High Affinity Nerve Growth Factor Receptor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Astellas Pharma Inc High Affinity Nerve Growth Factor Receptor Product Portfolio Table 119. Astellas Pharma Inc Recent Development Table 120. Array BioPharma Inc Company Information Table 121. Array BioPharma Inc Business Overview Table 122. Array BioPharma Inc High Affinity Nerve Growth Factor Receptor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Array BioPharma Inc High Affinity Nerve Growth Factor Receptor Product Portfolio Table 124. Array BioPharma Inc Recent Development Table 125. Research Programs/Design for This Report Table 126. Authors List of This Report Table 127. Secondary Sources Table 128. Primary Sources List of Figures Figure 1. High Affinity Nerve Growth Factor Receptor Product Image Figure 2. Global High Affinity Nerve Growth Factor Receptor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global High Affinity Nerve Growth Factor Receptor Market Size (2021-2032) & (US$ Million) Figure 4. Global High Affinity Nerve Growth Factor Receptor Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cenegermin Image Figure 8. CRB-0089 Image Figure 9. BNN-27 Image Figure 10. AZD-7451 Image Figure 11. ASP-7962 Image Figure 12. Others Image Figure 13. Global High Affinity Nerve Growth Factor Receptor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global High Affinity Nerve Growth Factor Receptor Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global High Affinity Nerve Growth Factor Receptor Sales Value Share by Type (2021-2032) Figure 16. Low Back Pain Image Figure 17. Papillary Thyroid Cancer Image Figure 18. Lung Cancer Image Figure 19. Bile Duct Cancer Image Figure 20. Others Image Figure 21. Global High Affinity Nerve Growth Factor Receptor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global High Affinity Nerve Growth Factor Receptor Sales Value Share 2021 VS 2025 VS 2032 Figure 23. Global High Affinity Nerve Growth Factor Receptor Sales Value Share by Application (2021-2032) Figure 24. Global High Affinity Nerve Growth Factor Receptor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 25. Global High Affinity Nerve Growth Factor Receptor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 26. North America High Affinity Nerve Growth Factor Receptor Sales Value (2021-2032) & (US$ Million) Figure 27. North America High Affinity Nerve Growth Factor Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Europe High Affinity Nerve Growth Factor Receptor Sales Value (2021-2032) & (US$ Million) Figure 29. Europe High Affinity Nerve Growth Factor Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Asia-Pacific High Affinity Nerve Growth Factor Receptor Sales Value (2021-2032) & (US$ Million) Figure 31. Asia-Pacific High Affinity Nerve Growth Factor Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 32. South America High Affinity Nerve Growth Factor Receptor Sales Value (2021-2032) & (US$ Million) Figure 33. South America High Affinity Nerve Growth Factor Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Middle East & Africa High Affinity Nerve Growth Factor Receptor Sales Value (2021-2032) & (US$ Million) Figure 35. Middle East & Africa High Affinity Nerve Growth Factor Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 36. USA High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. USA High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. USA High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Canada High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Canada High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Canada High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Mexico High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Mexico High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Mexico High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Germany High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Germany High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Germany High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. France High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. France High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. France High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. U.K. High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. U.K. High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. U.K. High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Italy High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Italy High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Italy High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Spain High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Spain High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Spain High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Russia High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Russia High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Russia High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Netherlands High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Netherlands High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Netherlands High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Nordic Countries High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Nordic Countries High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Nordic Countries High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. China High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. China High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. China High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Japan High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Japan High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Japan High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. South Korea High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. South Korea High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. South Korea High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. India High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. India High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. India High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Australia High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Australia High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Australia High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Southeast Asia High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Southeast Asia High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Southeast Asia High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Brazil High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Brazil High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Brazil High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Argentina High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Argentina High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Argentina High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Chile High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Chile High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Chile High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Colombia High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Colombia High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Colombia High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Peru High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Peru High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Peru High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Saudi Arabia High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Saudi Arabia High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Saudi Arabia High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Israel High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Israel High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Israel High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. UAE High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. UAE High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. UAE High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Turkey High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Turkey High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Turkey High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Iran High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Iran High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Iran High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Egypt High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Egypt High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Egypt High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Years Considered Figure 121. Research Process Figure 122. Key Executives Interviewed

Scope & coverage.

Types
  • Cenegermin
  • CRB-0089
  • BNN-27
  • AZD-7451
  • ASP-7962
  • Others
Applications
  • Low Back Pain
  • Papillary Thyroid Cancer
  • Lung Cancer
  • Bile Duct Cancer
  • Others
Companies covered
  • Merck & Co Inc
  • AstraZeneca Plc
  • Tiziana Life Sciences Plc
  • Sienna Biopharmaceuticals Inc
  • Rottapharm Biotech Srl
  • Proximagen Ltd
  • Plexxikon Inc
  • Nerviano Medical Sciences Srl
  • Loxo Oncology Inc
  • Ignyta Inc
  • Handok Inc
  • Genzyme Corp
  • Dompe Farmaceutici SpA
  • Daiichi Sankyo Co Ltd
  • Astellas Pharma Inc
  • Array BioPharma Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global High Affinity Nerve Growth Factor Receptor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global High Affinity Nerve Growth Factor Receptor Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 High Affinity Nerve Growth Factor Receptor Market Dynamics
  1. 2.1 High Affinity Nerve Growth Factor Receptor Industry Trends
  2. 2.2 High Affinity Nerve Growth Factor Receptor Industry Drivers
  3. 2.3 High Affinity Nerve Growth Factor Receptor Industry Opportunities and Challenges
  4. 2.4 High Affinity Nerve Growth Factor Receptor Industry Restraints
3 High Affinity Nerve Growth Factor Receptor Market by Company
  1. 3.1 Global High Affinity Nerve Growth Factor Receptor Company Revenue Ranking in 2025
  2. 3.2 Global High Affinity Nerve Growth Factor Receptor Revenue by Company (2021-2026)
  3. 3.3 Global High Affinity Nerve Growth Factor Receptor Company Ranking (2024-2026)
  4. 3.4 Global High Affinity Nerve Growth Factor Receptor Company Manufacturing Base and Headquarters
  5. 3.5 Global High Affinity Nerve Growth Factor Receptor Company Product Type and Application
  6. 3.6 Global High Affinity Nerve Growth Factor Receptor Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global High Affinity Nerve Growth Factor Receptor Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 High Affinity Nerve Growth Factor Receptor Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 High Affinity Nerve Growth Factor Receptor Market by Type
  1. 4.1 High Affinity Nerve Growth Factor Receptor Type Introduction
  2. 4.1.1 Cenegermin
  3. 4.1.2 CRB-0089
  4. 4.1.3 BNN-27
  5. 4.1.4 AZD-7451
  6. 4.1.5 ASP-7962
  7. 4.1.6 Others
  8. 4.2 Global High Affinity Nerve Growth Factor Receptor Sales Value by Type
  9. 4.2.1 Global High Affinity Nerve Growth Factor Receptor Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global High Affinity Nerve Growth Factor Receptor Sales Value by Type (2021-2032)
  11. 4.2.3 Global High Affinity Nerve Growth Factor Receptor Sales Value Share by Type (2021-2032)
5 High Affinity Nerve Growth Factor Receptor Market by Application
  1. 5.1 High Affinity Nerve Growth Factor Receptor Application Introduction
  2. 5.1.1 Low Back Pain
  3. 5.1.2 Papillary Thyroid Cancer
  4. 5.1.3 Lung Cancer
  5. 5.1.4 Bile Duct Cancer
  6. 5.1.5 Others
  7. 5.2 Global High Affinity Nerve Growth Factor Receptor Sales Value by Application
  8. 5.2.1 Global High Affinity Nerve Growth Factor Receptor Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global High Affinity Nerve Growth Factor Receptor Sales Value by Application (2021-2032)
  10. 5.2.3 Global High Affinity Nerve Growth Factor Receptor Sales Value Share by Application (2021-2032)
6 High Affinity Nerve Growth Factor Receptor Regional Value Analysis
  1. 6.1 Global High Affinity Nerve Growth Factor Receptor Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global High Affinity Nerve Growth Factor Receptor Sales Value by Region (2021-2032)
  3. 6.2.1 Global High Affinity Nerve Growth Factor Receptor Sales Value by Region: 2021-2026
  4. 6.2.2 Global High Affinity Nerve Growth Factor Receptor Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America High Affinity Nerve Growth Factor Receptor Sales Value (2021-2032)
  7. 6.3.2 North America High Affinity Nerve Growth Factor Receptor Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe High Affinity Nerve Growth Factor Receptor Sales Value (2021-2032)
  10. 6.4.2 Europe High Affinity Nerve Growth Factor Receptor Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific High Affinity Nerve Growth Factor Receptor Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific High Affinity Nerve Growth Factor Receptor Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America High Affinity Nerve Growth Factor Receptor Sales Value (2021-2032)
  16. 6.6.2 South America High Affinity Nerve Growth Factor Receptor Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa High Affinity Nerve Growth Factor Receptor Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa High Affinity Nerve Growth Factor Receptor Sales Value Share by Country, 2025 VS 2032
7 High Affinity Nerve Growth Factor Receptor Country-level Value Analysis
  1. 7.1 Global High Affinity Nerve Growth Factor Receptor Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global High Affinity Nerve Growth Factor Receptor Sales Value by Country (2021-2032)
  3. 7.2.1 Global High Affinity Nerve Growth Factor Receptor Sales Value by Country (2021-2026)
  4. 7.2.2 Global High Affinity Nerve Growth Factor Receptor Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt High Affinity Nerve Growth Factor Receptor Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt High Affinity Nerve Growth Factor Receptor Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt High Affinity Nerve Growth Factor Receptor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck & Co Inc
  2. 8.1.1 Merck & Co Inc Company Information
  3. 8.1.2 Merck & Co Inc Business Overview
  4. 8.1.3 Merck & Co Inc High Affinity Nerve Growth Factor Receptor Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck & Co Inc High Affinity Nerve Growth Factor Receptor Product Portfolio
  6. 8.1.5 Merck & Co Inc Recent Developments
  7. 8.2 AstraZeneca Plc
  8. 8.2.1 AstraZeneca Plc Company Information
  9. 8.2.2 AstraZeneca Plc Business Overview
  10. 8.2.3 AstraZeneca Plc High Affinity Nerve Growth Factor Receptor Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca Plc High Affinity Nerve Growth Factor Receptor Product Portfolio
  12. 8.2.5 AstraZeneca Plc Recent Developments
  13. 8.3 Tiziana Life Sciences Plc
  14. 8.3.1 Tiziana Life Sciences Plc Company Information
  15. 8.3.2 Tiziana Life Sciences Plc Business Overview
  16. 8.3.3 Tiziana Life Sciences Plc High Affinity Nerve Growth Factor Receptor Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Tiziana Life Sciences Plc High Affinity Nerve Growth Factor Receptor Product Portfolio
  18. 8.3.5 Tiziana Life Sciences Plc Recent Developments
  19. 8.4 Sienna Biopharmaceuticals Inc
  20. 8.4.1 Sienna Biopharmaceuticals Inc Company Information
  21. 8.4.2 Sienna Biopharmaceuticals Inc Business Overview
  22. 8.4.3 Sienna Biopharmaceuticals Inc High Affinity Nerve Growth Factor Receptor Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sienna Biopharmaceuticals Inc High Affinity Nerve Growth Factor Receptor Product Portfolio
  24. 8.4.5 Sienna Biopharmaceuticals Inc Recent Developments
  25. 8.5 Rottapharm Biotech Srl
  26. 8.5.1 Rottapharm Biotech Srl Company Information
  27. 8.5.2 Rottapharm Biotech Srl Business Overview
  28. 8.5.3 Rottapharm Biotech Srl High Affinity Nerve Growth Factor Receptor Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Rottapharm Biotech Srl High Affinity Nerve Growth Factor Receptor Product Portfolio
  30. 8.5.5 Rottapharm Biotech Srl Recent Developments
  31. 8.6 Proximagen Ltd
  32. 8.6.1 Proximagen Ltd Company Information
  33. 8.6.2 Proximagen Ltd Business Overview
  34. 8.6.3 Proximagen Ltd High Affinity Nerve Growth Factor Receptor Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Proximagen Ltd High Affinity Nerve Growth Factor Receptor Product Portfolio
  36. 8.6.5 Proximagen Ltd Recent Developments
  37. 8.7 Plexxikon Inc
  38. 8.7.1 Plexxikon Inc Company Information
  39. 8.7.2 Plexxikon Inc Business Overview
  40. 8.7.3 Plexxikon Inc High Affinity Nerve Growth Factor Receptor Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Plexxikon Inc High Affinity Nerve Growth Factor Receptor Product Portfolio
  42. 8.7.5 Plexxikon Inc Recent Developments
  43. 8.8 Nerviano Medical Sciences Srl
  44. 8.8.1 Nerviano Medical Sciences Srl Company Information
  45. 8.8.2 Nerviano Medical Sciences Srl Business Overview
  46. 8.8.3 Nerviano Medical Sciences Srl High Affinity Nerve Growth Factor Receptor Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Nerviano Medical Sciences Srl High Affinity Nerve Growth Factor Receptor Product Portfolio
  48. 8.8.5 Nerviano Medical Sciences Srl Recent Developments
  49. 8.9 Loxo Oncology Inc
  50. 8.9.1 Loxo Oncology Inc Company Information
  51. 8.9.2 Loxo Oncology Inc Business Overview
  52. 8.9.3 Loxo Oncology Inc High Affinity Nerve Growth Factor Receptor Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Loxo Oncology Inc High Affinity Nerve Growth Factor Receptor Product Portfolio
  54. 8.9.5 Loxo Oncology Inc Recent Developments
  55. 8.10 Ignyta Inc
  56. 8.10.1 Ignyta Inc Company Information
  57. 8.10.2 Ignyta Inc Business Overview
  58. 8.10.3 Ignyta Inc High Affinity Nerve Growth Factor Receptor Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Ignyta Inc High Affinity Nerve Growth Factor Receptor Product Portfolio
  60. 8.10.5 Ignyta Inc Recent Developments
  61. 8.11 Handok Inc
  62. 8.11.1 Handok Inc Company Information
  63. 8.11.2 Handok Inc Business Overview
  64. 8.11.3 Handok Inc High Affinity Nerve Growth Factor Receptor Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Handok Inc High Affinity Nerve Growth Factor Receptor Product Portfolio
  66. 8.11.5 Handok Inc Recent Developments
  67. 8.12 Genzyme Corp
  68. 8.12.1 Genzyme Corp Company Information
  69. 8.12.2 Genzyme Corp Business Overview
  70. 8.12.3 Genzyme Corp High Affinity Nerve Growth Factor Receptor Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Genzyme Corp High Affinity Nerve Growth Factor Receptor Product Portfolio
  72. 8.12.5 Genzyme Corp Recent Developments
  73. 8.13 Dompe Farmaceutici SpA
  74. 8.13.1 Dompe Farmaceutici SpA Company Information
  75. 8.13.2 Dompe Farmaceutici SpA Business Overview
  76. 8.13.3 Dompe Farmaceutici SpA High Affinity Nerve Growth Factor Receptor Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Dompe Farmaceutici SpA High Affinity Nerve Growth Factor Receptor Product Portfolio
  78. 8.13.5 Dompe Farmaceutici SpA Recent Developments
  79. 8.14 Daiichi Sankyo Co Ltd
  80. 8.14.1 Daiichi Sankyo Co Ltd Company Information
  81. 8.14.2 Daiichi Sankyo Co Ltd Business Overview
  82. 8.14.3 Daiichi Sankyo Co Ltd High Affinity Nerve Growth Factor Receptor Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Daiichi Sankyo Co Ltd High Affinity Nerve Growth Factor Receptor Product Portfolio
  84. 8.14.5 Daiichi Sankyo Co Ltd Recent Developments
  85. 8.15 Astellas Pharma Inc
  86. 8.15.1 Astellas Pharma Inc Company Information
  87. 8.15.2 Astellas Pharma Inc Business Overview
  88. 8.15.3 Astellas Pharma Inc High Affinity Nerve Growth Factor Receptor Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Astellas Pharma Inc High Affinity Nerve Growth Factor Receptor Product Portfolio
  90. 8.15.5 Astellas Pharma Inc Recent Developments
  91. 8.16 Array BioPharma Inc
  92. 8.16.1 Array BioPharma Inc Company Information
  93. 8.16.2 Array BioPharma Inc Business Overview
  94. 8.16.3 Array BioPharma Inc High Affinity Nerve Growth Factor Receptor Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Array BioPharma Inc High Affinity Nerve Growth Factor Receptor Product Portfolio
  96. 8.16.5 Array BioPharma Inc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst